-
Change of publication date of the annual report for 2022
Read More
March 10, 2023 -
Conclusion of an agreement concerning the operational execution of Phase II of Phase I/II clinical trial of RVU120 in Patients with Relapsed/Refractory Solid Tumors
Read More
March 2, 2023 -
Receipt from a person discharging managerial responsibilities in the Company of a correction to the Article 19 MAR notification
Read More
February 6, 2023 -
Notification from a person discharging managerial responsibilities in the Company – Article 19 of MAR
Read More
February 3, 2023 -
Notification from a person discharging managerial responsibilities in the Company – Article 19 of MAR
Read More
February 3, 2023 -
Achievement of the first milestone under licence agreement with Exelixis Inc.
Read More
January 26, 2023 -
Announcement of the NDS on registration of series J shares with the NDS
Read More
January 25, 2023 -
Publication dates for periodic reports in 2023
Read More
January 25, 2023 -
Notification from TFI Allianz Polska S.A. of a change in its share in the total number of votes in the Company
Read More
January 25, 2023 -
Admission and introduction of the series J shares of the Company to trading on the regulated market of the WSE
Read More
January 20, 2023
Report: Current Stock Reports
Title